Skip to Content
CPTAC team labs

Target Request for Antibody Production and Characterization

NCI’s Antibody Characterization Program is seeking cancer-related protein targets for antibody development. Submissions due on or before July 9, 2012.

Read more.

Clinical Proteomic Tumor Analysis Consortium

The National Cancer Institute (NCI), part of the National Institutes of Health, announced the launch of a Clinical Proteomic Tumor Analysis Consortium (CPTAC) in August 2011. CPTAC is a comprehensive and coordinated effort to accelerate the understanding of the molecular basis of cancer through the application of robust, quantitative, proteomic technologies and workflows. Read more.  

PublicationsRSS

  • Drake PM, Schilling B, Niles RK, Prakobphol A, Li B, Jung K, Cho W, Braten M, Inerowicz HD, Williams K, Albertolle M, Held JM, Iacovides D, Sorensen DJ, Griffith OL, Johansen E, Zawadzka AM, Cusack MP, Allen S, Gormley M, Hall SC, Witkowska HE, Gray JW, Regnier F, Gibson BW, Fisher SJ. (2012) Lectin Chromatography/Mass Spectrometry Discovery Workflow Identifies Putative Biomarkers of Aggressive Breast Cancers J Proteome Res . Epub ahead of print. View pubmed abstract.
  • Zimmerman LJ, Li M, Yarbrough WG, Slebos R, Liebler DC. (2012) Global stability of plasma proteomes for mass spectrometry-based analyses. Mol Cell Proteomics . [Epub ahead of print] View pubmed abstract.
  • Mertins P, Udeshi ND, Clauser KR, Mani DR, Patel J, Ong SE, Jaffe JD, Carr SA. (2011) iTRAQ labeling is superior to mTRAQ for quantitative global proteomics and phosphoproteomics. Mol Cell Proteomics . [Epub ahead of print] View PubMed abstract.

View All »

Launch Antibody Portal »

The Antibody Portal serves as a public resource of monoclonal antibodies made available by the NCI for the scientific community to support protein/peptide measurement and analysis efforts.

Questions About Cancer